Clinical Trials Browser

Terminated × Breast Neoplasms × exemestane × Clear all

NCT01897441 2024-12-24

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

Phase NA Terminated

31 enrolled 11 charts

Breast

Breast Neoplasms

NCT05065411 2024-02-26

VERU-024

Phase 3 Terminated

5 enrolled

Breast

Breast Neoplasms

NCT04869943 2024-01-26

ARTEST

Phase 3 Terminated

52 enrolled

Breast

Breast Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT03874325 2022-05-31

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Phase 2 Terminated

17 enrolled 10 charts

Breast

Breast Neoplasms

NCT03220178 2022-01-06

PRECYCLE

Phase 4 Terminated

532 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00905021 2020-07-24

EXTENT

Phase 1/2 Terminated

4 enrolled 6 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01627067 2020-06-19

Exemestane-RAD001-Metformin

Phase 2 Terminated

23 enrolled 7 charts

Breast

Breast Neoplasms

NCT02983604 2019-08-07

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

Phase 1/2 Terminated

14 enrolled 13 charts

Breast

Breast Neoplasms

NCT01484041 2018-02-09

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Phase 1/2 Terminated

12 enrolled 7 charts

Breast

Breast Neoplasms

NCT00684216 2017-09-14

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

Phase 2/3 Terminated

10 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00194792 2017-07-11

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

Phase 2 Terminated

28 enrolled 9 charts

Breast

Breast Neoplasms

NCT00066807 2016-10-28

PERCHE

Phase 3 Terminated

29 enrolled 6 charts

Breast

Breast Neoplasms

NCT00573755 2016-02-05

Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer

Phase 2 Terminated

4 enrolled 8 charts

Breast

Breast Neoplasms

NCT00372996 2015-10-28

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Phase 2 Terminated

219 enrolled 11 charts

Breast

Breast Neoplasms

NCT01149356 2015-05-25

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

Phase 1 Terminated

15 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00776659 2013-11-19

An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin

Terminated

39 enrolled 7 charts

Breast

Breast Neoplasms

NCT00674557 2013-07-10

Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer

Phase 2 Terminated

111 enrolled

Breast

Breast Neoplasms

NCT00793546 2012-11-05

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

Phase 2 Terminated

42 enrolled 7 charts

Breast

Breast Neoplasms

NCT01239745 2012-10-31

Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer

Terminated

46 enrolled 9 charts

Breast

Breast Neoplasms

NCT01155063 2012-10-01

Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients

Terminated

89 enrolled 12 charts

Breast

Breast Neoplasms

NCT01305239 2012-04-10

ETAPE

Terminated

398 enrolled 10 charts

Breast

Breast Neoplasms

NCT00040014 2012-02-16

Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women

Phase 2 Terminated

100 enrolled

Breast

Breast Neoplasms

NCT00417885 2010-09-21

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

Phase 1/2 Terminated

6 enrolled 6 charts

Breast

Breast Neoplasms

NCT00810706 2008-12-18

ATENA

Phase 3 Terminated

448 enrolled

Breast

Breast Neoplasms